As of September 30, 2026, Tango Therapeutics, Inc. carries a market capitalization of 4.22B, placing it among publicly traded companies globally. Its enterprise value stands at 3.28B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 4.22B |
| Enterprise Value | 3.28B |
Tango Therapeutics, Inc.'s next confirmed earnings release is scheduled for March 29, 2027.
| Earnings Date | 3/29/2027 |
As of September 30, 2026, Tango Therapeutics, Inc. has 169.21M shares outstanding.
| Shares Outstanding | 169.21M |
These figures are as of September 30, 2026.
| PB Ratio | 4.31 |
| P/TBV Ratio | 4.31 |
| P/FCF Ratio | -24.86 |
| P/OCF Ratio | -24.89 |
As of September 30, 2026, Tango Therapeutics, Inc. maintains a current ratio of 39.45, meaning it holds 39.5x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 39.45 |
| Quick Ratio | 38.85 |
| Debt / Equity | 3.18 |
| Debt / EBITDA | -0.14 |
Over the twelve months ended September 30, 2026, Tango Therapeutics, Inc. posted a negative return on equity (ROE) of -36.48, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -33.45, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 137.00, a quick read on workforce productivity versus industry peers.
| Return on Equity (ROE) | -36.48 |
| Return on Assets (ROA) | -33.45 |
| Employee Count | 137.00 |
Over the twelve months ended September 30, 2026, Tango Therapeutics, Inc. recorded an income tax benefit of -53,000.00 rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -208.05M and -208.00M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.
| Income Tax | -53,000.00 |
As of the close on November 16, 2026, Tango Therapeutics, Inc.'s stock has gained approximately 195.84% over the past 52 weeks. The 50-day moving average sits at 23.56, while the 200-day moving average is 22.96.
| 52-Week Price Change | 195.84% |
| 50-Day Moving Average | 23.56 |
| 200-Day Moving Average | 22.96 |
Over the twelve months ended September 30, 2026, Tango Therapeutics, Inc. generated - - in revenue and converted that into -208.00M in net income, yielding earnings per share of -1.39. EBITDA reached -226.75M, while operating income came in at -228.53M.
| Operating Income | -228.53M |
| Pretax Income | -208.05M |
| Net Income | -208.00M |
| EBITDA | -226.75M |
| EBIT | -228.53M |
| Earnings Per Share (EPS) | -1.39 |
As of September 30, 2026, Tango Therapeutics, Inc. holds 977.50M in cash and equivalents against 31.18M in total debt, resulting in a net debt position of -86.83M. Total book value stands at 980.17M, with working capital of 967.50M providing operational flexibility.
| Cash & Cash Equivalents | 977.50M |
| Total Debt | 31.18M |
| Net Debt | -86.83M |
| Equity (Book Value) | 980.17M |
| Book Value Per Share | 5.79 |
| Working Capital | 967.50M |
Tango Therapeutics, Inc. produced -150.09M in operating cash flow over the twelve months ended September 30, 2026. After subtracting -222,000.00 in capital expenditures, free cash flow totaled -150.31M - equivalent to -1.00 per share.
| Operating Cash Flow | -150.09M |
| Capital Expenditures | -222,000.00 |
| Free Cash Flow | -150.31M |
| FCF Per Share | -1.00 |
These figures cover the twelve months ended September 30, 2026. Free cash flow yield is negative at -4.02: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -23.08, meaning Tango Therapeutics, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.
| Shareholder Yield | -23.08 |
| FCF Yield | -4.02 |
As of September 30, 2026, Tango Therapeutics, Inc. has an Altman Z-Score of 46.88, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 46.88 |